From: vector6@space.com Subject: Re: [ibogaine] what changed? Date: June 30, 2002 at 11:58:04 PM EDT To: ibogaine@mindvox.com Reply-To: ibogaine@mindvox.com This is for Kerry not Carrie 🙂 Kerry I don’t know that much about addiction and don’t do any drugs I want to stop doing, I hang at this place because…
From: “Ashley” <ashley1980@iamwasted.com> Subject: [ibogaine] hi! Date: May 31, 2002 at 10:56:01 PM EDT To: ibogaine@mindvox.com Reply-To: ibogaine@mindvox.com Hi nobody answers any of my emails so far. Please reply! This place is so dope! Awesome awesome! But I am totally lost. Where is this? I saw the logos up at…
From: “JONATHAN R. ARMSTRONG” <jonarmst@du.edu> Subject: Re: [ibogaine] Re: [crystaldomains@hotmail.com: A Friend…..] Date: February 27, 2002 at 2:42:55 PM EST To: “Patrick K. Kroupa” <digital@phantom.com> Cc: ibogaine@mindvox.com It’s a long shot, but is the molecular structure of hydergine in any way similar to ergotamine, ergonovine, etc? It would be interesting…
[The Global Ibogaine Therapist Alliance (GITA) released a series of reboots and updates to Howard Lotsof’s Ibogaine Treatment Manual.] Clinical Guidelines for Ibogaine-Assisted Detoxification Originally Published: September 2015 Current Version: 1.1 (February 25, 2016) Authors: Jonathan Dickinson Jamie McAlpin, R.N. Clare Wilkins Christine Fitzsimmons, R.N. Paige Guion, R.N. Tanea Paterson Douglas…
Copyright Omni Publications International Ltd. 1993 Omni July, 1993 SECTION: Vol. 15 ; No. 9 ; Pg. 14; ISSN: 0149-8711 LENGTH: 757 words HEADLINE: The mystery of ibogaine: can an African psychedelic cure addiction? BYLINE: Nadis, Steve BODY: Wild claims have been made about ibogaine, an hallucinogenic substance derived from…
NCTR 2002-2003 Research Plans – Neurotoxicology Title: Effects of Ibogaine on Neurotransmitter Systems, Generation of Free Radicals and Nitric Oxide Synthase Activity: Correlation with Neurohistological Evaluations in Mouse and Rat Brain Determine the effects of ibogaine on dopamine, serotonin and their metabolite concentrations in different regions of mouse and rat…
Ibogaine Patents @ the United States Patent Office (USPO) Use of ibogaine in reducing excitotoxic brain damage Use of ibogaine in reducing excitotoxic brain damage This invention discloses that ibogaine, a plant derivative, can be used as a safe NMDA antagonist at relatively high dosages (including dosages high enough to…
18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. 18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse. Like ibogaine (40 mg/kg), 18-MC…
Feature: Seeking Ways to Crack Cocaine Addiction The Lancet [Volume 352, Number 9136] 17 October 1998 by Kelly Morris The use of cocaine, a highly addictive stimulant and euphoriant with few physical withdrawal symptoms, is increasing. Up to 10% of ever-users will become heavy users, particularly if they inject the…
Science & Medicine: Data Accrue on “Visionary” Agent to Interrupt Addiction The Lancet [Volume 354, Number 9193] 27 November 1999 by Kelly Morris Few therapies exist for drug addiction, and unfortunately one agent that has shown promise– the plant alkaloid ibogaine–is mostly given in unsafe settings by addict self-help groups,…